Trial Profile
A Phase 2, dose- range finding, 12-week, double-blind, randomized, parallel group study to evaluate safety and efficacy of GRC 27864 in patients with moderate osteoarthritis pain
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Zaloglanstat (Primary)
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 14 Jul 2020 Status changed from active, no longer recruiting to completed.
- 12 Nov 2019 According to an Ichnos Sciences media release, topline results are expected in the first half of 2020.
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting according to an Ichnos Sciences media release.